id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15842 R65217 |
Bromley (Levetiracetam) (Controls exposed to LTG), 2023 | Small for gestation (calculated using gender-specific scales) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.67 [0.24;1.86] C excluded (control group) |
6/70 13/106 | 19 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15843 R65230 |
Bromley (Levetiracetam) (Controls unexposed, sick), 2023 | Small for gestation (calculated using gender-specific scales) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.48 [0.17;1.35] C | 6/70 13/80 | 19 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12550 R47240 |
Dreier (Levetiracetam), 2021 | Small for gestational age (birth weight below the 10th percentile for GA, sex and country) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.13 [0.92;1.39] | -/1,019 -/- | - | 1,019 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12619 R47572 |
Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021 | Small for gestational age (weight for gestational age <10th percentile) | at least 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.75 [0.26;2.19] C excluded (control group) |
6/89 9/102 | 15 | 89 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12616 R47554 |
Van Marter (Levetiracetam) (Controls unexposed, sick), 2021 | Small for gestational age (weight for gestational age <10th percentile) | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.13 [0.11;39.98] C | 6/89 0/14 | 6 | 89 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8083 R24690 |
Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
7.00 [0.30;164.40] C excluded (control group) |
3/10 0/7 | 3 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8081 R24670 |
Aydin (Levetiracetam) (Controls unexposed, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 23.15 [1.05;509.05] C | 3/10 0/22 | 3 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7807 R23112 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.40 [1.11;1.77] C | 82/621 167,376/1,710,441 | 167,458 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5932 R15145 |
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.73 [0.12;59.97] C excluded (control group) |
0/13 2/173 | 2 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5913 R14936 |
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
2.00 [0.12;33.85] C excluded (control group) |
0/13 14,079/719,509 | 14,079 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5921 R15032 |
Artama (Levetiracetam) (Controls unexposed, sick), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 1.65 [0.10;28.29] C | 0/13 42/1,793 | 42 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 1.21 [0.89;1.64] | 167,528 | 1,822 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam; 3: Levetiracetam) (Controls unexposed, sick; 4: Levetiracetam) (Controls unexposed, sick; 5: Levetiracetam) (Controls unexposed, NOS; 6: Levetiracetam) (Controls unexposed, sick;
Asymetry test p-value = 0.7254 (by Egger's regression)
slope=0.1656 (0.1555); intercept=0.3085 (0.8187); t=0.3768; p=0.7254
excluded 5932, 5913, 8083, 12619, 15842